다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Current opinion in immunology, v.24 no.3, 2012년, pp.316 - 323
Stamatatos, Leonidas (Seattle BioMed and the University of Washington, Seattle, WA, United States)
AI-Helper
Highlights► Broadly neutralizing antibodies against HIV are generated during infection, but so far, not by vaccination. ► Recently, MAbs with potent and broad anti-HIV neutralizing activities were isolated from HIV-infected subjects. ► The study of these new MAbs informs us o...
Science Barre-Sinoussi 220 868 1983 10.1126/science.6189183 Isolation of a T-lympotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
Science Gallo 224 500 1984 10.1126/science.6200936 Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
Nature Luciw 312 760 1984 10.1038/312760a0 Molecular cloning of AIDS-associated retrovirus
Science Popovic 224 497 1984 10.1126/science.6200935 Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
J Infect Dis Mascola 173 340 1996 10.1093/infdis/173.2.340 Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
Curr HIV Res Hu 5 507 2007 10.2174/157016207782418542 Prospects of HIV Env modification as an approach to HIV vaccine design
Annu Rev Immunol Mascola 28 413 2010 10.1146/annurev-immunol-030409-101256 The role of antibodies in HIV vaccines
J Exp Med Koup 180 779 1994 10.1084/jem.180.3.779 Virus escape from CTL recognition [comment]
J Virol Koup 68 4650 1994 10.1128/JVI.68.7.4650-4655.1994 Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
Lancet Buchbinder 372 1881 2008 10.1016/S0140-6736(08)61591-3 Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
N Engl J Med Rerks-Ngarm 361 2209 2009 10.1056/NEJMoa0908492 Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
N Engl J Med Haynes 366 1275 2012 10.1056/NEJMoa1113425 Immune-correlates analysis of an HIV-1 vaccine efficacy trial
J Virol Moore 68 5142 1994 10.1128/JVI.68.8.5142-5155.1994 Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1
J Virol Tomaras 82 12449 2008 10.1128/JVI.01708-08 Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
Proc Natl Acad Sci USA Richman 100 4144 2003 10.1073/pnas.0630530100 Rapid evolution of the neutralizing antibody response to HIV type 1 infection
Proc Natl Acad Sci USA Frost 102 18514 2005 10.1073/pnas.0504658102 Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection
Trans Am Clin Climatol Assoc Richman 115 289 2004 HIV evolution and escape
Nature Wei 422 307 2003 10.1038/nature01470 Antibody neutralization and escape by HIV-1
J Virol Dhillon 81 6548 2007 10.1128/JVI.02749-06 Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
J Virol Doria-Rose 84 1631 2010 10.1128/JVI.01482-09 Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables
PLoS Pathog Mikell 7 e1001251 2011 10.1371/journal.ppat.1001251 Characteristics of the earliest cross-neutralizing antibody response to HIV-1
J Virol Sather 83 757 2009 10.1128/JVI.02036-08 Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
J Virol Simek 83 7337 2009 10.1128/JVI.00110-09 Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm
AIDS van Gils 23 2405 2009 10.1097/QAD.0b013e32833243e7 Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression
PLoS ONE Mouquet 6 e24078 2011 10.1371/journal.pone.0024078 Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses
J Immunol Methods Scheid 343 65 2009 10.1016/j.jim.2008.11.012 A method for identification of HIV gp140 binding memory B cells in human blood
Science Scheid 333 1633 2011 10.1126/science.1207227 Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
Proc Natl Acad Sci USA Burton 102 14943 2005 10.1073/pnas.0505126102 Antibody vs. HIV in a clash of evolutionary titans
Science Wu 329 856 2010 10.1126/science.1187659 Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
Science Walker 326 285 2009 10.1126/science.1178746 Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
Science Pejchal 334 1097 2011 10.1126/science.1213256 A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield
Nature Walker 477 466 2011 10.1038/nature10373 Broad neutralization coverage of HIV by multiple highly potent antibodies
Nature McLellan 480 324 2011 10.1038/nature10696 Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Proc Natl Acad Sci USA Pejchal 107 11483 2010 10.1073/pnas.1004600107 Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1
Science Diskin 334 1289 2011 10.1126/science.1213782 Increasing the potency and breadth of an HIV antibody by using structure-based rational design
Science Wu 333 1593 2011 10.1126/science.1207532 Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
Virology Choudhry 363 79 2007 10.1016/j.virol.2007.01.015 Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies
J Acquir Immune Defic Syndr Posner 6 7 1993 Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120
J Virol Roben 68 4821 1994 10.1128/JVI.68.8.4821-4828.1994 Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
J Virol Thali 67 3978 1993 10.1128/JVI.67.7.3978-3988.1993 Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
J Virol Gorny 79 5232 2005 10.1128/JVI.79.8.5232-5237.2005 Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles
Science Chen 326 1123 2009 10.1126/science.1175868 Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120
J Virol Pantophlet 77 642 2003 10.1128/JVI.77.1.642-658.2003 Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120
J Virol Kraft 81 6402 2007 10.1128/JVI.00424-07 Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies
Proc Natl Acad Sci USA Walker 108 20125 2011 10.1073/pnas.1117531108 Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque
AIDS Res Hum Retroviruses Shibata 8 403 1992 10.1089/aid.1992.8.403 SIV/HIV recombinants and their use in studying biological properties
J Virol Shibata 65 3514 1991 10.1128/JVI.65.7.3514-3520.1991 Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells
J Virol Igarashi 76 379 2002 10.1128/JVI.76.1.379-391.2002 Rapid and irreversible CD4+ T-cell depletion induced by the highly pathogenic simian/human immunodeficiency virus SHIV(DH12R) is systemic and synchronous
Virology Luciw 263 112 1999 10.1006/viro.1999.9908 Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques
J Virol Reimann 70 6922 1996 10.1128/JVI.70.10.6922-6928.1996 A chimeric simian/human immunodeficiency virus expresing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
J Virol Chen 74 6501 2000 10.1128/JVI.74.14.6501-6510.2000 Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina)
Science Harouse 284 816 1999 10.1126/science.284.5415.816 Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs
Proc Natl Acad Sci USA Luciw 92 7490 1995 10.1073/pnas.92.16.7490 Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV)
J Virol Nishimura 84 4769 2010 10.1128/JVI.02279-09 Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques
J Virol Song 80 8729 2006 10.1128/JVI.00558-06 Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env
J Virol Robinson 84 3443 2010 10.1128/JVI.02617-09 Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4
Nat Med Baba 6 200 2000 10.1038/72309 Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
J Virol Mascola 73 4009 1999 10.1128/JVI.73.5.4009-4018.1999 Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
Nat Med Mascola 6 207 2000 10.1038/72318 Protection of macaques against vaginal transmission of a pathogenic HIV- 1/SIV chimeric virus by passive infusion of neutralizing antibodies
Nat Med Hessell 15 841 2009 10.1038/nm.1974 Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
PLoS Pathog Hessell 5 e1000433 2009 10.1371/journal.ppat.1000433 Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
J Virol Hessell 84 1302 2010 10.1128/JVI.01272-09 Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L
J Virol Parren 75 8340 2001 10.1128/JVI.75.17.8340-8347.2001 Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
Proc Natl Acad Sci USA Nishimura 100 15131 2003 10.1073/pnas.2436476100 Transfer of neutralizing IgG to macaques 6h but not 24h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development
Proc Natl Acad Sci USA Burton 108 11181 2011 10.1073/pnas.1103012108 Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
Nature Hessell 449 101 2007 10.1038/nature06106 Fc receptor but not complement binding is important in antibody protection against HIV
J Mol Biol Correia 405 284 2011 10.1016/j.jmb.2010.09.061 Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design
Structure Correia 18 1116 2010 10.1016/j.str.2010.06.010 Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope
Proc Natl Acad Sci USA Ofek 107 17880 2010 10.1073/pnas.1004728107 Elicitation of structure-specific antibodies by epitope scaffolds
Science Haynes 308 1906 2005 10.1126/science.1111781 Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
Immunity Sun 28 52 2008 10.1016/j.immuni.2007.11.018 HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane
Science Azoitei 334 373 2011 10.1126/science.1209368 Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold
Viruses Xiao 1 802 2009 10.3390/v1030802 Maturation pathways of cross-reactive HIV-1 neutralizing antibodies
J Exp Med Liao 208 2237 2011 10.1084/jem.20110363 Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
Nature Kasturi 470 543 2011 10.1038/nature09737 Programming the magnitude and persistence of antibody responses with innate immunity
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.